GLP-1 market heats up as companies vie for next-gen obesity drugs
Oct 31, 2024 · Since the FDA approval of Novo Nordisk’s Wegovy as a treatment for chronic weight management in 2021, followed by the approval of Ozempic the next year, demand for GLP-1 agonist drugs has rapidly grown.
Noema Pharma Secures $147M to Advance CNS Disorder …
Dec 12, 2024 · Noema Pharma has announced an extension of its series B financing round, bringing the total raised up to $147 million (CHF 130 million). The round extension has seen venture capital firm EQT Life Sciences join the Swiss company’s existing investors, which include Forbion, Jeito Capital, Sofinnova Partners, and Gilde Healthcare among others.
Symbiosis unveils expanded facility at CPHI Milan 2024
Oct 2, 2024 · The event provides a great platform for the company to present its newest addition—a 20,000 sq ft facility in Stirling, UK, which the company says enhances Symbiosis' ability to support biopharma companies with high-quality manufacturing solutions.
Novo Nordisk signs $285 million deal for a once-monthly Wegovy
Nov 7, 2024 · Ascendis Pharma has granted Novo Nordisk an exclusive worldwide license to its TransCon technology platform for the development, manufacturing and commercialization of Novo’s products in metabolic diseases, including obesity and type 2 diabetes.
Vetter Pharma International
Vetter is a leading global contract development and manufacturing organization (CDMO) for the aseptic production of injectables. Our headquarters are in Ravensburg, Germany, where we have been a family-owned company since our start as a pharmacy in 1950.
How eCOA/ePRO is transforming clinical trials
Nov 25, 2024 · (Image: Getty/Spainter_vfx) Q: What trends do you see shaping eCOA/ePRO in the next year? SR: Personalization and adaptability are big ones.Patients want tailored experiences, so platforms will need to adapt to individual needs — whether that’s through language options, integration with personal devices, or customized notifications.
AbbVie acquires Nimble for oral peptides
Dec 17, 2024 · “The talented, passionate and dedicated team at Nimble has made great progress over the past few years and we are pleased that AbbVie has recognized the tremendous potential of our proprietary platform and emerging immunology pipeline.”
NorthStar launches radiopharmaceutical CDMO
Oct 24, 2024 · The increasing integration of medical radioisotopes with diagnostic and molecular imaging as well as the rise of personalized medicine is spurring the growth of the global market for these products, which was valued at $5.1 billion in 2022 and is expected to soar by 8.8% per year to $11.4 billion by 2032. NorthStar’s peers in the field include Nordion, Isotopen Technologien München (ITM ...
$680M deal with CBC and Mubadala shifts UCB's strategy
Aug 29, 2024 · The $680 million transaction, announced on August 26, involves the sale of established brands such as Keppra, Vimpat, Neupro, Zyrtec, and Xyzal, along with UCB's Zhuhai manufacturing site, to CBC Group and Mubadala Investment Company.
How will the Biosecure Act impact the pharma industry?
Oct 8, 2024 · But what does the Act mean for the biotech and pharma industry and how can companies best prepare for any impacts on future business? The Biosecure Act was first proposed by the US government late last year due to concerns about national security and how genetic and other biological data could be misused by foreign adversarial governments with a focus on China.